Media Coverage

The U.S. Food and Drug Administration’s expert advisory committee is meeting today to discuss the emergency use authorization of Johnson & Johnson’s Covid-19 vaccine. If authorized, it will be the first single-dose Covid-19 vaccine. Despite some confusing data about its efficacy compared with other vaccines, this new one-shot vaccine has the potential to substantially ease the logistical problems that we’ve seen to date. Healthcare systems, especially in the 130 countries that have yet to give out their first shots, should pay close attention. Americans should, too. First, consider the efficacy issue. Compared to the eye-popping 95% efficacy levels of the two-dose Moderna and Pfizer vaccines, Johnson & Johnson’s 66% efficacy at preventing moderate and severe disease might seem disappointing. But it is important to realize that 66% is a very high efficacy level in absolute terms.

Walmart is leveraging its ubiquity and logistical know-how to become a major player in the national vaccine rollout, offering vaccinations across its roughly 5,000 Walmart and Sam’s club stores.

Fewer than half of the provinces and territories have online booking systems up and running so members of the public can make their appointments for the largest vaccination campaign in Canadian history. Some of those that have launched their systems have faced crashes and bugs.

Millions of Americans are not getting their second dose of the coronavirusvaccine within the recommended time period for ensuring optimal protection from COVID-19, according to a CBS MoneyWatch review of the latest data from the U.S. Centers for Disease Control and Prevention.

WASHINGTON (CN) — President Joe Biden signed an executive order Wednesday afternoon to boost crucial supply chains that have been suffering due to the pandemic.